Mark Breidenbach
Stock Analyst at Oppenheimer
(1.68)
# 3,290
Out of 5,182 analysts
48
Total ratings
30.91%
Success rate
1.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.25 | +211.11% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.49 | +81.93% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $10.29 | +823.23% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $5.76 | +334.03% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $300 | $17.93 | +1,573.17% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $7.32 | +3,178.69% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.23 | +7,062.04% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.92 | +139.73% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $2.13 | +1,402.35% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $3.43 | +337.32% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.76 | +1,282,794.74% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.25
Upside: +211.11%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.49
Upside: +81.93%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $10.29
Upside: +823.23%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $5.76
Upside: +334.03%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $300
Current: $17.93
Upside: +1,573.17%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $7.32
Upside: +3,178.69%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.23
Upside: +7,062.04%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.92
Upside: +139.73%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $2.13
Upside: +1,402.35%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.43
Upside: +337.32%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.76
Upside: +1,282,794.74%